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n this issue of Kidney Interna-
tional Reports, Perrone and co-
workers1,2 describe the results of 2
phase 2 studies comparing 2 for-
mulations of tolvaptan; the
immediate-release form (IR) and a
new, modified-release form (MR).
Tolvaptan is a vasopressin V2
receptor antagonist. This medicine
was granted market authorization
by the European Medicines
Agency in 2015 and by the U.S.
Food and Drug Administration in
2018 for use in patients with
autosomal dominant polycystic
kidney disease (ADPKD) with
normal to moderately reduced
kidney function and whose disease
is progressing rapidly. Tolvaptan
blocks the vasopressin V2 recep-
tor, and, via inhibition of adenylyl
cyclase, the generation of cyclic
AMP in collecting duct cells,
resulting in decreased cyst growth
and attenuation of renal function
decline in ADPKD.3 Scientific evi-
dence for the beneficial effects of
this drug in patients with ADPKD
has been provided by the TEMPOCorrespondence: Esther Meijer, Division
of Nephrology, Department of Medicine,
University Medical Center Groningen, PO
Box 30.001, 9700 RB Groningen, The
Netherlands. E-mail: esther.meijer@
umcg.nl
7623:4 trial4 and the REPRISE study,5
which showed a decrease in
growth rate of total kidney volume
of 49% and a decrease in estimated
glomerular filtration rate on treat-
ment by 26% to 35% in patients
with ADPKD early and later in the
disease.
The obvious downside of treat-
ment with a vasopressin V2 re-
ceptor antagonist (V2RA) is the
resultant impairment of urinary
concentrating capacity and conse-
quently aquaresis. Subjects treated
with the V2RA have an average
urine volume of 6 to 8 l/d, noctu-
ria, and thirst. In the TEMPO 3:4
trial, 8.3% of patients treated with
tolvaptan discontinued treatment
because of aquaresis-related
symptoms. For some patients (and
also for some nephrologists), this is
a reason not to initiate treatment at
all. In others, it was a reason to
down-titrate to lower dosages,
which may have less efficacy as we
reason in the following para-
graphs. To accommodate patients,
Perrone et al.,1,2 investigated, in 2
different studies published in this
issue of Kidney International Re-
ports, whether 1 daily dose of a
new MR tablet of tolvaptan has
similar efficacy but a better toler-
ability profile than the IR formu-
lation that must be taken twiceKidney International Reports (2020) 5, 762–765daily and that was used in the
clinical trials.
The first study is a multicenter,
parallel-arm, randomized placebo-
controlled dose-ranging study.1 In
2 study arms, 12 patients with
ADPKD had 3 cross-over periods,
using 7-day split-dose treatments
(IR) versus MR formulation com-
bined with placebo. Doses used
wereMR 20 mg,MR 40mg (given as
MR 20þMR20mg),MR 60mg,MR
120 mg, and IR 90þ30. There were
dose-dependent increases in phar-
macokinetics and pharmacody-
namics that were comparable forMR
and IR formulations. Urinary
burden was dependent on the dose
of tolvaptan, not on the formulation.
The second study, the
NOCTURNE randomized trial,
investigated short-term efficacy
and tolerability for 2 MR doses and
1 IR dose.2 In this trial, 177 pa-
tients with ADPKD early in the
disease (mean estimated glomerular
filtration rate 81) were randomized
in a 1:1:1:1 ratio to tolvaptan MR
80 mg/placebo, tolvaptan MR 50
mg/placebo, tolvaptan IR 60/30
mg, or placebo/placebo during 8
weeks. After 3 weeks of treatment,
in all MR groups, total kidney
volume decreased with 2.0% to
2.5% compared with baseline; in
the IR group this was lower,
with 1.17%. Mean urinary os-
molarity was 408 in placebo, 207
for MR 50 mg, 159 for MR 80 mg,
and 157 for IR 60/30. Remarkably,
the IR 90/30-mg dose was not
tested. Frequencies of thirst, noc-
turia, polyuria, and pollakiuria
increased with dose, but were not
different between the 2 formula-
tions. Also, quality of life was not
different for the different formu-
lations of tolvaptan.
The main conclusion of these 2
studies was that pharmacodynamic
effects and also aquaretic side ef-
fects increase with increasing dose.
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or in quality of life were observed,
when comparing MR and IR for-
mulations. This is disappointing,
because it indicates that the new
MR preparation is not the answer
to the clinically relevant question
of how to improve tolerability to
V2RAs. Notwithstanding, these 2
studies are of interest also, because
they touch on some issues that are
worth discussing, to improve
rational prescription of this drug
in daily practice.
The first issue to discuss is the
efficacy outcome that was used.
Because it was a short-term study,
no firm conclusions can be drawn
on the most important efficacy
outcome, that is, the rate of kidney
function decline. In the
NOCTURNE study, change in
kidney volume after 3 weeks was
chosen as the surrogate efficacy
parameter. Such a short-term
change in volume may reflect
only a temporary effect on fluid
secretion into cysts, and cannot be
indicative for a structural benefit
of tolvaptan to preserve kidney
architecture and functioning kid-
ney tissue. Moreover, in the
NOCTURNE trial, change in kid-
ney volume for the MR formula-
tions was different from baseline,
but for the IR formulation this was
not the case, although this formu-
lation is proven to be renopro-
tective on longer term, again an
indication that it is difficult to
translate this short-term effect on
total kidney volume into a sus-
tained decrease in rate of renal
function decline over time.
The second issue is tolerability.
Because these studies used in the
treatment arms with the MR
preparation an additional placebo
to match for the evening dose of
the IR form, the intake of medica-
tion once versus twice daily cannot
be investigated. It seems more
patient-friendly to take only 1
instead of 2 pills. On the otherKidney International Reports (2020) 5, 762–765hand, the aquaretic effects are
immediately absent after skipping
1 dose. This means that patients
who take tolvaptan IR twice daily
have the possibility to skip the
afternoon dose and, for instance,
can go to a theater without having
to miss scenes because of toilet
visits caused by aquaresis-driven
polyuria. Patients who take the
slow-release formulation of tol-
vaptan in the morning will not
have this possibility.
The third issue is the dose of the
IR formulation of tolvaptan that
was used in NOCTURNE. The au-
thors state that this 60/30-mg dose
was chosen because it was used in
most clinical trials. This is, how-
ever, not the case. In the previ-
ously described landmark trials of
tolvaptan in ADPKD,4,5 subjects
were uptitrated to 120 mg (90/30
split-dose). Those who did not
tolerate this dose, could be down-
titrated to the highest tolerable
dose. In the TEMPO trial, 55%
tolerated this 120-mg dose,
whereas 21% tolerated only 90 (60/
30) mg and 24% only 60 (45/15)
mg. In REPRISE, 61% used 120
(90/30) mg. Thus, renoprotective
efficacy has been proven for a
treatment strategy in which pa-
tients are uptitrated to 120 mg or
the highest tolerated dose. There is
no evidence that administration of
lower dosages will be as effective.
We therefore advocate to use in
clinical practice the same dosing
strategy, that is, target for 120 (90/
30) mg/d.
To improve tolerability, alter-
native dosing strategies have been
proposed that do not primarily aim
for prescribing 120 mg/d, but at
inducing a urine osmolarity <300
mOsmol/l. The latter strategy
would generally result in less 24-
hour urine volume. The 2 trials in
this issue1,2 also use this osmolarity
cutoff. The rationale for this strat-
egy is based on the results of a post
hoc study of the TEMPO 3:4 trial.6In this study, it was found that
when tolvaptan-treated subjects
are divided into quartiles of uri-
nary osmolarity at the end of
treatment phase, subjects with a
value <251 mOsmol/l (i.e., quar-
tiles 1, 2, and 3) have approxi-
mately the same annual rate of
estimated glomerular filtration rate
decline. The authors therefore
suggest that inducing an addi-
tional decrease in urinary osmo-
larity with tolvaptan will not
further improve treatment effi-
cacy. However, both baseline kid-
ney function and tolvaptan have
an effect on urine osmolarity and
both are associated with disease
outcome. This makes it difficult to
dissect treatment effect on rate of
kidney function decline. For
instance, in this post hoc study,
subjects in the quartile with
highest urinary osmolarity on tol-
vaptan treatment (i.e., a urinary
osmolarity >250 mOsmol/l) actu-
ally had the highest baseline esti-
mated glomerular filtration rate
and the lowest rate of kidney
function decline thereafter. This
reflects probably their intrinsic
better disease prognosis, that
would have been more favorable
even without treatment. These
latter data should not be used to
decide that lowering tolvaptan
dose to achieve a higher urinary
osmolarity on treatment would be
beneficial. We therefore believe
that no firm conclusions can be
drawn based on these non-
randomized, observational post hoc
analyses of urine osmolarity data.
It makes sense that if urinary os-
molarity can decrease further from
for instance 251 to 140 mOsmol/l
by increasing tolvaptan dose,
apparently there was residual
vasopressin activity that can be
inhibited, and perhaps this addi-
tional vasopressin inhibition re-
sults in more treatment effect. The
dose-dependent decrease in uri-
nary osmolarity is also shown in763
Figure 1. The V2 receptor antagonist tolvaptan induces a decrease in urine osmolarity that
is dose dependent until the highest dose used in trials and in clinical practice. *P < 0.05;
** P < 0.01; ***P < 0.001.
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lished in this issue (where 56%
reached a urinary osmolarity <300
mOsmol/l when using MR 60 mg
versus 92% when using MR 120
mg) and described in literature.7
We also see this phenomenon in
our patients, who we uptitrate to
the highest tolerable dose. Urinary
osmolarity decreases when upti-
trating from 60/30 mg to 90/30 mg
(Figure 1). Figure 1 also shows that
some patients already have a uri-
nary osmolarity <300 mOsmol/l
before starting tolvaptan. These
are especially patients with more
severe disease, which has impaired
their ability to concentrate urine.
Such patients may have particular
benefit of tolvaptan, again indi-
cating that this urinary osmolarity
threshold of <300 mOsmol/l
cannot be used as a marker to764titrate tolvaptan dose to achieve
maximal renoprotection.
Some nephrologists decrease the
dose of tolvaptan when urinary
osmolarity is <300 mOsmol/l to
improve tolerability. As explained,
we do not favor such a strategy.We
often observe that when disease
progresses, 24-hour urinary vol-
ume decreases again under treat-
ment and consequently that
urinary osmolarity increases. In
such patients, we increase the dose
of the V2RA based on an animal
study that showed beneficial effects
when tolvaptan was uptitrated to
maintain a high urinary volume
and low urine osmolarity.8 Of
course, we realize this will not help
to improve tolerability of the drug,
but in our opinion it is important
that we first take care that treat-
ment efficacy on rate of diseaseprogression is maintained. To
improve tolerability, 2 alternative
strategies come to mind. Because
therapy with tolvaptan mimics
nephrogenic diabetes insipidus (a
blocked vs. a defective receptor),
the same treatment strategies are
likely to help. When concentrating
capacity is impaired due to the
V2RA, and consequently urine os-
molarity is near the maximal urine
dilution capacity value, the amount
of osmoles ingested will dictate the
level of aquaresis. The first strategy
to lower urine volume is therefore
to decrease salt and protein intake.9
But also taking the last meal some
hours earlier will likely help to
decrease the level of nocturia. The
second strategy is to add medica-
tion. In nephrogenic diabetes
insipidus, hydrochlorothiazide
effectively decreases polyuria by
increasing absorption of sodium
and water in the proximal tubule.
Whether this treatment also works
in patients with tolvaptan-induced
diabetes insipidus is safe and does
not influence the renoprotective
efficacy of tolvaptan in ADPKD re-
mains to be studied.
In conclusion, the 2 studies
published in this issue found
similar pharmacodynamics and
tolerability for tolvaptan MR
versus IR. An MR preparation is
therefore not the answer to the
question of how to improve toler-
ability of tolvaptan. To do so,
without compromising the reno-
protective efficacy of this drug, we
suggest investigating other treat-
ment strategies, that is, copre-
scribing a low osmolar diet and/or
anti-aquaretic drugs such as
hydrochlorothiazide.DISCLOSURE
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